by Raynovich Rod | Jul 17, 2018 | Biopharmaceuticals
Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck...
by Raynovich Rod | Apr 24, 2018 | Biopharmaceuticals
Update 4/25: Investors May See Value in Large Cap Biotech Amgen (AMGN) up 1.68%. Biogen (BIIB) holds Tuesday lows of $262 Up 2.78% today. IBB flat at $103.26 More earnings tomorrow but it is all about technicals holding the recent bottom. ========== Biotech Sector...
by Raynovich Rod | Apr 9, 2018 | Biopharmaceuticals
Updates 4/11/18 Biotechs Holding Above Recent Bottom 4/6/18 FBT up 2.8% over 5 days, up 6% YTD XBI up 1.77% over 5 days, up 2.19% YTD IBB down 0.72% over 5 days, down 3.67% YTD Busted Biotechs Review In our “Busted Biotechs” article we said that the XBI...
by Raynovich Rod | Oct 16, 2017 | Biopharmaceuticals
Risks Rising for Healthcare Sector As Harsh Political Rhetoric Returns Trump returns to drug pricing attacks. Healthcare sector lags. Opioid crisis blames drug distribution companies for easy access. Sector on hold awaiting Q3 earnings: XLV down 0.44% today near its...
by Raynovich Rod | Sep 14, 2017 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Markets Stable After Major FED Meeting: On Course for Gradual QT(Quantitative Tightening) FED to shrink assets by year end, 2 yr TSY up to 1.43% yield. Biotech stocks up slightly near September Top IBB $332.75, XBI $85.17. Large caps green: growth and value perceived:...
by Raynovich Rod | May 8, 2017 | Biopharmaceuticals
May 8, 2017 Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics: Best stock performance YTD are REGN up 15.3%, AMGN up...
by Raynovich Rod | Apr 25, 2017 | 2024 Rayno Biopharmaceuticals Portfolio
Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for...
by Raynovich Rod | Apr 15, 2017 | Biopharmaceuticals
Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at...
by Raynovich Rod | Jan 2, 2017 | Biopharmaceuticals
Update-2…1/6/17– Three Day Biotech Rally…12N EST NASDAQ at New Highs 5532 XBI is up 5 points since last Friday’s close to $63.45;The IBB is up 16 points to $280. Investors are betting on a turnaround in healthcare with positive news from the...
by Raynovich Rod | Nov 29, 2016 | Biopharmaceuticals
Market Reversal in Biotech Offers Bullish Set-Up After one of the worst down days in months yesterday biotech stocks broadly reversed today giving a short term “nibble” signal. The macro environment got support from economic data as well with upward Q3 GDP...